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Inhibitors that activate
The RAS-extracellular signal–regulated protein kinase (ERK)–
mitogen-activated protein kinase (MAPK) signaling pathway 
regulates cell responses to environmental signals and plays 
a critical role in cancer in humans. As a result, this complex 
pathway is a particularly appealing target for therapeutic inter-
vention in oncology, especially because activating mutations 
in KRAS and BRAF are found in more than 30% of all human 
tumors and in 40% of melanomas. Indeed, selective inhibitors 
of RAF have been developed and are currently in clinical tri-
als. Recently, several groups reported that selective RAF kinase 
inhibitors can activate the MAPK pathway via CRAF and drive 
tumor progression. In back-to-back reports, Poulikakos et al. and 
Hatzivassilou et al. demonstrated that these ATP-competitive 
inhibitors exhibited two opposing actions depending on cel-
lular context. In the presence of the common BRAF(V600E) 
mutation, the RAF inhibitors blocked MAPK signaling and 
decreased tumor growth; in the absence of this mutation, how-
ever, RAF inhibitors activated the RAF–MEK–ERK pathway in a 
RAS-dependent manner and enhanced tumor growth in some 
models. In addition, Heidorn and colleagues showed that 
BRAF selective inhibitors induce RAS-dependent BRAF binding 
to CRAF, subsequent CRAF activation, and MEK–ERK signal-
ing. Mutant Braf that lacks kinase activity mimicked the effects 
of the BRAF inhibitors and cooperated with oncogenic Ras to 
induce melanoma in mice.
These findings impact the potential clinical use of these 
inhibitor molecules. For example, RAF inhibitors may prove 
useful in treating tumors driven by BRAF(V600E); however, the 
same molecules may deleteriously affect tumors in the absence 
of this mutation via activation of ERK signaling. In addition, 
these results underscore the importance of understanding this 
complex signaling pathway in tumorigenesis and highlight the 
need for obtaining a genetic mutation signature for tumors in 
order to allow personalized treatment strategies to be imple-
mented. (Cell 140:209–21, 2010; Nature 464:427–30, 2010; 
Nature 464:431–5, 2010)
Signals from the niche
The mechanisms that underlie the maintenance of melanocyte 
stem cells in the bulge by the surrounding niche environ-
ment are not known. Because a role for cytokine transform-
ing growth factor-β (TGF-β) in stem cell quiescence has been 
suggested for hematopoietic, prostate, and neural stem cells, 
Nishimura and colleagues examined the function of this niche-
derived factor on melanocyte stem cell entry into quiescence. 
In these studies, TGF-β signaling was activated when melano-
cyte stem cells entered the dormant stage during the hair cycle 
to maintain their immaturity. In addition, TGF-β-induced cell 
cycle arrest downregulated the master transcriptional regulator 
of melanocyte development Mitf; suppressed expression of 
melanogenic genes, including tyrosinase in melanocytes; and 
induced dramatic morphological changes. Furthermore, the 
antiapoptotic molecule Bcl2 was required for cell survival 
because TGF-β triggered melanocyte stem cell apoptosis in 
the absence of this factor. Taken together, these results demon-
strate that TGF-β signaling is essential for melanocyte stem cell 
entry and maintenance in the quiescent state. (Cell Stem Cell 
6:130–40, 2010)
Regulatory T cells take the fall
Granulocyte colony-stimulating factor (G-CSF) is commonly 
used to mobilize stem cells for use in allogeneic hema topoietic 
stem cell transplantation (SCT). Use of this technique has led to 
an increase in graft-versus-host disease (GVHD) in SCT patients, 
although the mechanisms are unknown. Hill and colleagues 
recently found that G-CSF influences T helper cell type 17 
(Th17) differentiation, and these responses appeared to domi-
nate any effects of this cytokine on Th1/Th2 differentiation. Of 
the cytokines involved in Th17 differentiation, IL-21 was found 
to be critical in the G-CSF-induced response. After SCT, donor 
CD8 T cells were a major source of IL-21. Importantly, donor 
CD8 T cells produced IL-17A after transplantation, and this 
cytokine controlled the infiltration of macrophages into the skin 
and the subsequent fibrotic response. Development of sclero-
derma, then, may occur in a CD4 T-cell-independent manner. 
Thus, these results shed light on the mechanisms of GVHD fol-
lowing SCT with G-CSF-mobilized stem cells and offer a poten-
tial point for therapeutic intervention. (Blood, published online 
30 April 2010; doi:10.1182/blood-2009-11-256495)
Digitized sequence comes to life
Over the past 25 years, our ability to rapidly digitize genomic 
information has increased dramatically. Using a complex strat-
egy for synthesis and assembly of the 1.08-Mbp Mycoplasma 
mycoides JCVI-syn1.0 genome, Gibson and colleagues recently 
reported the successful transplantation of this synthetic genome 
into a recipient Mycoplasma capricolum bacterial cell. This 
new bacterial cell, which exhibited the characteristics of M. 
mycoides, was controlled entirely by the synthetic M. mycoides 
genome. This “synthetic cell” provides proof of principle that 
living cells can be produced on the basis of computer-gener-
ated genomic sequences. Although this process of genome 
synthesis is quite expensive and labor-intensive, DNA synthe-
sis will probably follow in the footsteps of DNA sequencing 
and become not only less expensive but also more automated, 
allowing this process to be applied to the synthesis and trans-
plantation of more novel genomes in the future. This exciting 
process of generation of live cells via novel genome construc-
tion will undoubtedly lead to philosophical issues with broad 
ethical implications. (Science, published online 20 May 2010; 
doi:10.1126/science.1190719)
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